AI-generated research brief — verify at source
Adding Trastuzumab to Chemoradiation Does Not Improve Patient-Reported Outcomes in HER2+ Esophageal Adenocarcinoma
Adding trastuzumab to trimodality therapy for HER2-overexpressing localized esophageal adenocarcinoma produced no meaningful improvement in patient-reported quality-of-life outcomes, with the proportion of patients reporting improved esophageal cancer subscale scores at 6–8 weeks nearly identical between arms (46% vs. 38%, no statistically significant difference, p = 0.39). The result reinforces the primary efficacy findings of NRG/RTOG 1010 and suggests that the addition of trastuzumab confers neither survival nor symptomatic benefit in this setting.
What Was Studied
This analysis addressed whether the addition of trastuzumab to standard chemoradiation and surgery — collectively known as trimodality therapy — would improve patient-reported outcomes (PROs) in patients with HER2-overexpressing localized esophageal adenocarcinoma. A secondary question examined whether achieving a pathologic complete response (pCR) at surgery was associated with better self-reported quality of life at one year, testing whether an objective tumor response translated into a patient-perceived benefit.
How It Was Studied
NRG/RTOG 1010 was a phase 3 randomized controlled trial enrolling HER2-positive localized esophageal adenocarcinoma patients between 2010 and 2015. Participants were assigned to either standard weekly paclitaxel, carboplatin, and concurrent radiation (chemoradiation, CRT) followed by surgery, or the same regimen with trastuzumab added (CRT + Tras). The primary endpoint of the parent trial was disease-free survival, while the PRO substudy aimed to enroll 158 consenting patients — approximately 80% of the 197-patient HER2-positive primary cohort — giving at least 89% statistical power to detect a 25% or greater increase in the proportion of patients on the trastuzumab arm reporting improved scores on the FACT-Esophageal Cancer Subscale (ECS). Of 194 eligible patients, 171 provided PRO consent, and ECS assessments were collected at baseline, 6–8 weeks post-chemoradiation, and at one and two years.
What Was Observed
- At the primary PRO time point of 6–8 weeks post-chemoradiation, 46% of patients on the trastuzumab arm reported improved ECS scores compared with 38% on the standard CRT arm — a difference that was not statistically significant (p = 0.39), meaning the data are consistent with no true difference between groups.
- There was no meaningful association between pathologic complete response and self-reported quality of life at one year: 39% of pCR patients and 37% of non-pCR patients reported improved ECS scores, indicating that achieving a tumor-free surgical specimen did not translate into a perceptibly better patient experience at that time point.
- PRO completion rates declined substantially over time — from 95% at baseline to 64% at 6–8 weeks, 49% at one year, and only 33% at two years — raising the possibility that attrition, potentially linked to disease progression or treatment-related burden, could have influenced longitudinal comparisons.
Why This Matters
The failure of trastuzumab to improve PROs in this trial is scientifically significant because HER2-targeted therapy has transformed outcomes in metastatic gastroesophageal disease, generating substantial interest in extending its use to localized settings. These PRO data add an important patient-centered dimension to the null efficacy result of the primary RTOG 1010 analysis and suggest that intensifying treatment with trastuzumab does not ease the symptomatic burden of a demanding trimodality regimen. The lack of correlation between pCR and one-year quality-of-life scores also challenges assumptions that tumor response surrogates reliably predict patient-perceived recovery.
How to Read This Result
Interpretation should be tempered by the substantial PRO attrition over time, which may have introduced selection bias and reduced the representativeness of later time-point comparisons, limiting confidence in the longitudinal quality-of-life estimates.
Limitations
The abstract does not explicitly report study limitations beyond what can be inferred from the declining PRO completion rates across assessment time points. The drop from 95% baseline completion to 33% at two years represents a notable attrition pattern that the abstract acknowledges through the reported figures but does not formally discuss as a methodological constraint.